Stephen J. Aselage's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 49,933 Automatic Stock Option Grant done . Disclosure was reported to the exchange on June 12, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 12 Jun 2024 | 49,933 | 49,933 | - | - | Automatic Stock Option Grant | ||
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 12 Jun 2024 | 6,820 | 70,159 (0%) | 0% | 0 | Common Stock | ||
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 24 May 2024 | 2,500 | 2,500 (0%) | 0% | 6.4 | 16,000 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 13 Jun 2023 | 39,072 | 39,072 | - | - | Automatic Stock Option Grant | ||
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 13 Jun 2023 | 16,745 | 63,339 (0%) | 0% | 0 | Common Stock | ||
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 07 Jun 2022 | 30,022 | 30,022 | - | - | Automatic Stock Option Grant | ||
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 07 Jun 2022 | 12,866 | 46,594 (0%) | 0% | 0 | Common Stock | ||
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 31 May 2022 | 569 | 33,728 (0%) | 0% | 9.3 | 5,297 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 21.93 per share. | 11 May 2022 | 2,575 | 146,919 (0%) | 0% | 21.9 | 56,457 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 28 Feb 2022 | 301 | 33,159 (0%) | 0% | 16.6 | 5,000 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 30 Nov 2021 | 414 | 32,858 (0%) | 0% | 12.1 | 4,993 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 29.39 per share. | 16 Nov 2021 | 31,800 | 149,494 (0%) | 0% | 29.4 | 934,602 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2021 | 10,000 | 70,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.23 per share. | 05 Nov 2021 | 10,000 | 161,794 (0%) | 0% | 26.2 | 262,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 05 Nov 2021 | 10,000 | 171,794 (0%) | 0% | 16.2 | 162,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Nov 2021 | 25,000 | 164,794 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Nov 2021 | 25,000 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 29.48 per share. | 01 Nov 2021 | 5,000 | 23,000 (0%) | 0% | 29.5 | 147,400 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 01 Nov 2021 | 3,500 | 19,500 (0%) | 0% | 30 | 105,000 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Nov 2021 | 3,000 | 28,000 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Nov 2021 | 3,000 | 161,794 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 07 Oct 2021 | 60,000 | 249,794 (0%) | 0% | 16.2 | 973,800 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2021 | 60,000 | 80,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.26 per share. | 07 Oct 2021 | 32,000 | 189,794 (0%) | 0% | 26.3 | 840,320 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.23 per share. | 07 Oct 2021 | 28,000 | 221,794 (0%) | 0% | 26.2 | 734,440 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 31 Aug 2021 | 314 | 32,444 (0%) | 0% | 15.9 | 4,999 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 28 May 2021 | 634 | 32,130 (0%) | 0% | 15.8 | 9,998 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 25 May 2021 | 40,000 | 40,000 | - | - | Automatic Stock Option Grant | ||
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,000 | 189,794 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 19.58 per share. | 11 May 2021 | 2,146 | 186,794 (0%) | 0% | 19.6 | 42,023 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 26.23 per share. | 16 Apr 2021 | 10,000 | 188,940 (0%) | 0% | 26.2 | 262,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 16 Apr 2021 | 10,000 | 198,940 (0%) | 0% | 16.2 | 162,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2021 | 10,000 | 140,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2021 | 10,000 | 150,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 27.35 per share. | 17 Mar 2021 | 10,000 | 196,667 (0%) | 0% | 27.4 | 273,500 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 17 Mar 2021 | 10,000 | 206,667 (0%) | 0% | 16.2 | 162,300 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 27.56 per share. | 17 Mar 2021 | 7,727 | 188,940 (0%) | 0% | 27.6 | 212,956 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Stephen J. Aselage | Director | 26 Feb 2021 | 927 | 31,496 (0%) | 0% | 10.8 | 9,993 | Common Stock | |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 02 Feb 2021 | 25,000 | 196,667 (0%) | 0% | 30.8 | 768,750 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.09 per share. | 02 Feb 2021 | 25,000 | 221,667 (0%) | 0% | 10.1 | 252,250 | Common Stock |
| Travere Therapeutics Inc | Stephen J. Aselage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 25,000 | 275,000 | - | - | Employee stock option (right to buy) |